Welcome

Sign out Have a question? We're here to help

Copyright © 2019 InvestorPlace Media, LLC. All rights reserved. 9201 Corporate Blvd, Rockville, MD 20850.

Editas Medicine (EDIT)

$22.66 0.33 (1.44%)

16:10 EST EDIT Stock Quote Delayed 15 Minutes

Volume:

Previous Close $22.99

Market Cap 1.08B

PE Ratio -8.09

EPS -2.8

Volume (Avg. Vol.) 538,811

Day's Range 22.24 - 23.26

52-Week Range 17.80 - 32.46

Dividend & Yield N/A (N/A)

EDIT Stock Predictions, Articles, and Editas Medicine News

From InvestorPlace
From the Web

3 Biotech Stocks That Are Set for a Breakthrough

By Matt McCall, Editor, MoneyWire Feb 1, 2019

If you're looking for biotech stocks to buy with massive breakthrough potential in gene editing, then these three are kings among the rest.

Gene Editing is a Major Technology to Watch

By Matt McCall, Editor, MoneyWire Aug 27, 2018

Gene-editing technology is going to be a game-changer in the future, which means the time to invest in CRISPR stocks is now.

Whole Foods Market, Inc. (WFM) and Xtant Medical Holdings Inc (XTNT) Lead 13 Activist Investment Filings

By Fintel May 31, 2017

13G and 13D filings are windows into activist investor activity. Latest filings include Whole Foods Markets, Inc., and these 12 other stocks

Analysts Have Lowered Expectations For Editas Medicine, Inc. After Its Latest Results

From Simply Wall St Nov 14, 2019

Editas Medicine, Inc. (NASDAQ:EDIT) missed earnings with its latest quarterly results, disappointing overly-optimistic analysts. The numbers were weak, with revenues of US$3.8m coming in 18% short of analyst estimates. Losses<div><a class="permalink" href="https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-edit/editas-medicine/news/analysts-have-lowered-expectations-for-editas-medicine-inc-after-its-latest-results/">Read More...</a></div>

Editas adds to Celgene collaboration-stoked up move, shares ahead 4%

From Seeking Alpha Nov 13, 2019

CRISPR/Cas9 gene editor Editas Medicine (EDIT +4%) is up on average volume, adding to yesterday's 9% jump after it announced an amended collaboration agreement with Celgene (CELG) aimed at researching

Editas (EDIT) Beats on Q3 Earnings, Amends Celgene Deal

From Zacks Investment Research Nov 13, 2019

Editas' (EDIT) portfolio currently lacks an approved product. The focus of third-quarter earnings call was on its pipeline development.

Editas Expands Its Celgene Partnership After Another Strong Quarter

From The Motley Fool Nov 13, 2019

With first patient dosing for EDIT-101 drawing near, Editas is powering forward with other promising medicines and partnerships.

Editas Medicine, Inc. (EDIT) Q3 2019 Earnings Call Transcript

From The Motley Fool Nov 13, 2019

EDIT earnings call for the period ending September 30, 2019.

Editas Medicine +5% on Q3 results

From Seeking Alpha Nov 12, 2019

Editas Medicine (EDIT +4.9%) Q3 results: Revenues: $3.8M (-73.8%).Net loss: ($32.9M) (-116.4%); loss/share: ($0.66) (-106.3%); Quick Assets: $332.6M (-9.9%).First patient dosing in Phase 1/2 EDIT-101

Navellier Ratings

Powered by Portfolio Grader

Total Grade

D

Sell

Free Report

10 Stocks Set for Monster Growth

He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!

Download your FREE COPY!